Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06965543Not ApplicableNot Yet Recruiting

G-POEM for Glycemic Control in Diabetic Gastroparesis

Role: lead

NCT06743386Not ApplicableNot Yet Recruiting

Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )

Role: lead

NCT02583087Unknown

ESD for the Treatment of Early Barrett's Neoplasia

Role: collaborator

NCT02078232Not ApplicableCompleted

Comparison of Two Needles (19G Flex Versus 22G Standard) for Pancreatic Solid Tumors Diagnosis

Role: lead

All 4 trials loaded